Genmab — Maj 2024
-
ASCO LBA out: Subcutaneous amivantamab vs intravenous amivantamab https://meetings.asco.org/abstracts-presentations/232405 . seems like a slam dunk.
-
end of the q2 EL
-
last day.crazy volume
-
ASCO24 Preview: A Look at Some of the Cancer Meeting’s Hottest Abstracts https://www.biospace.com/article/asco-2024-preview-a-look-at-some-of-the-cancer-meeting-s-hottest-abstracts
-
'On June 3, researchers will be presenting Phase II data on Pfizer and Genmab’s Tivdak (tisotumab vedotin) in head and neck squamous cell carcinoma. Analysts from Leerink Partners were encouraged by the data, positing that they “could see antibody drug-conjugates (ADCs) eventually replace chemotherapy in [the] head and neck cancer treatment paradigm, particularly in the second line space,” according to a report.
-
-
Today, the robust clinical development of Amivantamab for EGFR-mutant NSCLC adds a new chapter looking towards a stronger future.
Soon, the Paloma-3 study will be discussed by Natasha Leighl.
Honored to have been part of this significant milestone https://x.com/apassaromd/status/1796614821670015322?s=61&t=Ry4q9LC1jDgQzC__0QIEPg
Det kan den desværre ikke svare på, men den kan bruges til at analysere tekster og komme med kvalificerede bud på baseret på hvad du har fodre den med.Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind